Pasithea Therapeutics (KTTA) Cash from Investing Activities (2021 - 2023)
Pasithea Therapeutics (KTTA) posted Cash from Investing Activities of $54536.0 for Q4 2023, up 8.73% sequentially from $50159.0 in Q3 2023, and up 102.33% YoY from $26954.2 in Q4 2022.
Pasithea Therapeutics (KTTA) Cash from Investing Activities (2021 - 2023) Analysis & Trends
Pasithea Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at $54536.0 in Q4 2023.
- Quarterly Cash from Investing Activities rose 102.33% year-over-year to $54536.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $75199.0 (up 103.27% YoY) and the FY2025 annual result came in at $11000.0, changed N/A from the prior year.
- Cash from Investing Activities grew to $54536.0 in Q4 2023 per KTTA's latest filing, from $50159.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $70121.0 in Q2 2022 and troughed at -$2.3 million in Q4 2022.
- A 3-year average of -$248603.7 and a median of -$1951.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 18007.96% in 2022, then soared 293.16% in 2023.
- Over 3 years, Cash from Investing Activities stood at -$12933.0 in 2021, then plunged by 18007.96% to -$2.3 million in 2022, then jumped by 102.33% to $54536.0 in 2023.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $54536.0, $50159.0, and $24392.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 54,536.00 |
| Dec 31, 2023 | 54,536.00 |
| Sep 30, 2023 | 50,159.00 |
| Sep 30, 2023 | 50,159.00 |
| Jun 30, 2023 | 24,392.00 |
| Jun 30, 2023 | 24,392.00 |
| Mar 31, 2023 | -53,888.00 |
| Mar 31, 2023 | -53,888.00 |
| Dec 31, 2022 | -2.34 Mn |
| Dec 31, 2022 | -2.34 Mn |
| Sep 30, 2022 | -25,967.00 |
| Sep 30, 2022 | -25,967.00 |
| Jun 30, 2022 | 70,121.00 |
| Jun 30, 2022 | 70,121.00 |
| Mar 31, 2022 | -1,951.00 |
| Mar 31, 2022 | -1,951.00 |
| Dec 31, 2021 | -12,933.00 |
| Dec 31, 2021 | -12,933.00 |